|
Carnosine:
the new anti-aging supplement
by Marios Kyriazis MD
Although
carnosine (also known as L-carnosine) has been known for about a century, its
antiaging properties have only been extensively studied during the past few
years. A recent literature review revealed over 780 published studies on
carnosine, mainly by Russian and Japanese researchers. However, more
widespread interest in this natural nontoxic product has only recently been
increased, fuelled by dramatic Australian and British discoveries about its
antiaging actions (1).
Carnosine
(B-alanyl-L-histidine) is a naturally-occurring di-peptide (a combination of two
amino acids), found in muscle, brain and other innervated animal and human
tissues. It is formed by a process involving the enzyme carnosine-synthetase
which bonds the amino acids alanine and histidine. This process occurs mainly in
muscles and brain. It is kept in equilibrium by the carnisinases which are
enzymes specifically aimed at inactivating carnosine in the tissues or in the
blood.
There
are several other related dipeptides such as carcinine, anserrine, homocarnosine
and ophidine, all of which are naturally-occurring. These are believed to be
buffering agents, helping to maintain the homeostatic equilibrium (2).
High
concentrations of carnosine are present in long-lived cells (such as in neuronal
tissues). The concentration of carnosine in muscles correlates with maximum
lifespan, a fact that makes it a promising bio-marker of aging.
It is high in actively contracting muscles and low in cases of muscular
disease such as Duchennes's muscular dystrophy. Its concentration in mammalian
muscles possibly decreases with age, a fact which strengthens the case for
supplementation.
In
cases of cataract in animals, carnosine concentration in the lens was found to
be low. The lower the concentration of carnosine, the higher the severity of
cataract. Rabbits fed on a high
cholesterol diet, were found to be well protected against atherosclerosis and
cataract if given carnosine supplements. In
another experiment, dogs were also found to be protected against cataract if
given carnosine supplements (2).
Antioxidant
Properties
Carnosine is widely believed to he an antioxidant which stabilizes and protects
the cell membrane. Specifically, as a water-soluble free radical scavenger it
prevents lipid peroxidation within the cell membrane (3). It is thought to be a
natural counterpart to lipid-soluble antioxidants such as vitamin E.
Maybe it is not a coincidence that carnosine increases vitamin E levels
in rats.
Many
antioxidants are aimed at preventing free radicals from entering the tissues,
but have no effect after this first line of defense is broken. Carnosine is not
only effective in prevention, but it is also active after f ree radicals react
to form other dangerous compounds. So, it protects the tissues from these
damaging 'second-wave' chemicals. For example, a highly reactive lipid
peroxidation end-product called malondialdegyde (MDA), a deleterious product of
a free radical reaction, is blocked by carnosine (4,5).
MDA, if left uncontrolled, can cause damage to lipids, enzymes and DNA,
and plays a part in the process of atherosclerosis, joint inflammation, cataract
formation, and aging in general. Carnosine,
by reacting and inactivating MDA, sacrifices itself in order to protect the
amino acids on the protein molecule.
Other
Benefits
Carnosine plays a part in neurotransmission, it is a heavy metal binder
(chelates ionic metals) and modulates enzymatic activities.
Other actions, some of which are not extensively studied include:
*
anti-neoplastic properties, which make it a potentially beneficial agent for use
in cancer prevention.
* immune booster (it stimulates maturation of immunocompetent cells), and
reduces inflammation.
* wound healing properties and protection against radiation damage (both
preventing damage and reversing the post-radiation syndrome).
Laboratory animals treated with carnosine were found to have faster and
better wound healing rates compared to controls. This has potential applications
to treating burns, wounds following surgery, or during nutritional preparation
for surgery (5).
* a reduction of gastric ulceration (particularly when the ulcer is related to
stress), both by preventing the formation of the ulcer and by healing it
(carnosine increases the formation of granulation tissue).
It does not affect acid secretion.
Glycosylation
Perhaps, the most important action of carnosine is its anti-glycosylation effect
(8). One of the cardinal processes of aging, apart from free-radical damage, is
the process of glycosylation (or glycation).
During normal, everyday metabolism, sugar aldehydes may react with the
mino acids on the protein molecule. The result is the formation of AGEs (Advance
Glycosylation End-products). These are abnormal, cross-linked. oxidized products
which are thought to cause extensive damage to the organism. Carnosine blocks
this deleterious reaction. protecting against cross-linking of proteins,
cross-linking of proteins to DNA molecules, and formation of other abnormal
proteins, all of which are fundamental features of the aging process.
Other
anti-glycators such as aminoguanidine may also protect against glycosylation hut
not as effectively as carnosine. Some amino acids (arginine or lysine) are also
able to combine with glucose in order to eliminate dangerous AGEs, but the
end-product of this reaction is mutagenic (i.e. it may cause cancer). The
combination of carnosine with glucose however is not mutagenic.
Specifically,
carnosine reacts with and inactivates aldehydes and ketones. reducing protein
glycosylation and the formation of AGEs. It also binds to already formed AGEs
and inactivates them. Normally, AGEs are removed by scavenging macrophages
(immune system cells) which carry special receptors called RAGEs. Carnosine
facilitates this process of elimination, by helping macrophages to better
recognize the AGE molecule. Because of its anti-glycosylation actions, carnosine
may be useful in treating or preventing diabetic complications such as cataract,
neuropathy and kidney failure.
Amyloid
Protection
In experiments, treatment with carnosine was found to reduce or completely
prevent cell damage caused by beta amyloid (9), the substance found in the brain
of Alzheimer's disease patients. Beta amyloid can interact with certain RAGE
receptors causing damage to the nerves and arteries of the brain. Carnosine
blocks and inactivates beta amyloid, so it protects neural tissues against
diseases such as dementia.
There
have been some concerns regarding carnosine's ability to form lipofuscin (the
age pigment commonly found in the aging brain and in other tissues). Lipofuscin
is merely a sign that other deleterious reactions have already taken place. For
example; free radicals and toxic aldehydes may react with valuable proteins as
described above, and cause damage, leaving lipofuscin as a left-over product.
(Ed.-it may be advisable to take a lipofuscin supplement such as DMAE or
acetyl-L-carnitine while on a carnosine program). One way to save the protein
molecule is to use carnosine instead. Carnosine
actively and swiftly binds to aldehydes before these are able to cause any
damage. The end-result of this reaction may also be inactive lipofuscin
compounds.
In
this case, lipofuscin is formed not by wasting
valuable protein material but by using sacrificial carnosine, leaving the
proteins free to function properly. Lipofuscin,
however formed, is thought to be generally inactive to normally everyday
situations. High amounts of free radicals and toxin in the organism are best
inactivated by using supplementary carnosine than tissue protein.
Of course, it would be best to reduce the exposure to too many free
radicals in the first place. This can be achieved for example, by avoiding
pollution, cigarette smoking, sedentary life, and unsuitable nutrition.
Use
on Humans
After dozens of reports about carnosine's antiaging actions in laboratory
experiments, the next logical step was to start using it on humans, specifically
for antiaging purposes. Carnosine supplements have been used in the past by
body-builders, athletes and others, but its use has been confined mainly for
improving muscular fatigue, and not for longevity.
Recently,
eye drops containing carnosine have been developed and used by Russian
researchers (10). The drops were found to be effective in treating human corneal
erosions and other corneal diseases. For example, carnosine drops accelerate the
healing of ulcers in herpes and bacterial infections of the eye.
During
a preliminary experiment designed specifically for antiaging (II), I used
L-carnosine supplements (50 rng daily) on 20 healthy human volunteers, aged 40 -
75 years, for a period of 1-4 months. No side affects were reported. Five users
noticed significant improvements in their facial appearance (firmer facial
muscles), muscular stamina and general well-being. Five others reported possible
benefits, for example better sleep patterns, improved clarity of thought and
increased libido. The rest did not report any noticeable effects.
This is not surprising because supplementation with carnosine is not
expected to show any significant noticeable benefits in a short time, but it
should be used as an insurance against deleterious effects of the aging process.
If any benefits are noted, these should be considered as an added extra bonus.
It is worthwhile persevering with the supplementation long term, even if you do
not experience any obvious benefits, as you will still be well protected against
aging.
Carnosine
can be used together with vitamin E and/or Co-enzyme Q10 for full antioxidant
protection, but even if it is used on its own it should still confer significant
protection both against free radicals and against glycosylation.
Indeed,
the carnosine preparation I used in my experiments contains also 30 IU of
vitamin E as standard. Other nutritional products such as (growth
hormone-releasers are fine to use with carnosine, if required. Some people
prefer to use 100 mg of carnosine a day (i.e. double the initial standard dose)
and they find that there are still no side effects. It may he preferable however
to only start with 50 mg a day under advice from your physician or nutritionist,
and only increase the dose if recommended following professional advice.
Foodstuffs containing dietary carnosineare lean red meat. and chicken.
Conclusion
Where do we go from here? Further
experiments are in progress, aimed at examining more widely the effects of
carnosine on human aging. Those who want to he at the forefront of innovative
antiaging medicine should he taking carnosine now. It is expected that carnosine
supplementation will become much more widespread during the next five years,
making carnosine as popular as vitamin E is today.
References
to order
1)
Hipkiss
A.
Carnosine. a protective, anti-ageing peptide? Int J Biochem Cell Biol. 1998, 30:
S63-868.
2)
Quinn PL Boldyrev AA. Formaziuk VH. Carnosine: its properties, functions and
potential therapeutic applications. Mol Aspects Mod, 1992, 13(5):379-444.
3)
Tarnha M, et al. Hydroxyl radical scavenging by carnosine and Cu(ii)-carm)sine
complexes. Int J Radial Biol, 1999 75(9):1 177-1188.
4)
Hipkiss A. et al. Protective effects of carnosine against MDA-induced toxicity
towards cultured rat brain endothelial cells. Neuroscience Letters. 1997.
135-138.
5)
Hipkiss A et al. Protective effects of carnosine against protein modification
mediated by nialondialdchyde and hypochlorite. Bioch Biophys Acta 1998,
1380;46-54.
6)
Roberts PR, Black KW, Santamauro JT. Dietary peptides improve wound healing
following surgery. Nutrition, 1998, 14(3):26h-2^9.
7)
McFarlandGA,HollidayR. Further evidence for the rejuvenating effects of the
dipeptide I-carnosine on cultured human diploid fibroblast. Exp Gerontol 1999
34(l):35-45.
8)
Hipkiss A, Ghana 14. Carnosine protects proteins against rnelhyiglyoxal-mediated
modicatiations. Biochem Biophys Rcs Goinm 1998. 248 (1); 28-32.
9)
Preston J et al. Toxic effects of B-amyloid on immortalised rat brain
endothelial cell: protection by carnosine, homocarnosine and B-alanine.
Neuroscience letters 1998, 242; 105-108.
10)
Maichuk luF, Formaziuk VF. Sergienku VI. Development of carnosine eye drops and
assessing their efficiency in corneal diseases. Vestn Oftalmol 1997.1
13(ft);27-31.
11
) Kynazis M. 1999. Data on file.
ALL INFORMATION IS EDUCATIONAL
AND PROVIDED UNDER IAS TERMS AND CONDITIONS AND SHOULD NOT
REPLACE THE ADVICE OF YOUR PHYSICIAN.
The above
article is copyrighted and may not be copied without the written permission of
International Antiaging Systems, Les Autelets Suite A, Sark GY9 0SF, Channel Islands,
UK
|